Search
- Feb 13
Taking a deep dive into the IgA nephropathy (IgAN) space with the CEO of Vera Therapeutics
Marshall Fordyce describes the rationale of targeting both BAFF and APRIL as a B-cell modulator for IgAN.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A